NVCR gains Japan NHI reimbursement for Optune Lua in advanced NSCLC, expanding patient access and supporting adoption of its ...

NovoCure (NASDAQ:NVCR) reported record fourth-quarter and full-year 2025 revenue on its latest earnings call, while outlining ...

Optune Lua Revenue -- $10.4 million for the year, including $5.8 million from non-small cell lung cancer; recognized $3.5 ...

Novocure (Nasdaq:NVCR) announced today that Japan’s Ministry of Health, Labour and Welfare approved reimbursement for its ...

Management issued guidance of $675 million to $705 million in net revenue for 2026, assuming Optune Gio net revenue growth in the low to mid-single digits and $15 million to $25 million in net revenue ...

In the assessment of 12-month price targets, analysts unveil insights for NovoCure, presenting an average target of $38.25, a high estimate of $49.00, and a low estimate of $18.00. This current ...

As of Wednesday, February 25, NovoCure Limited’s NVCR share price has surged by 17.21%, which has investors questioning if this is right time to sell.

NovoCure Limited (NASDAQ:NVCR) Q4 2025 Earnings Call Transcript February 26, 2026 NovoCure Limited beats earnings expectations. Reported EPS is $-0.21978, expectations were $-0.41. Operator: Good day, ...

NovoCure Ltd (NASDAQ: NVCR) shares are trending on Thursday. Shares of the oncology company surged 29.52% to $13.60 in after-hours trading on Wednesday after the Food and Drug Administration approved ...

The FDA gave the go-ahead to Novocure for its tumor-treating electric fields device that targets advanced pancreatic cancer in conjunction with the drugs gemcitabine and nab-paclitaxel. The approval ...